These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3841034)

  • 1. Evidence against a vasopressor role of ADH in malignant DOC-salt hypertension.
    Filep J; Frölich JC; Fejes-Toth G
    Clin Exp Hypertens A; 1985; 7(10):1457-70. PubMed ID: 3841034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of vasopressin blockade on blood pressure in conscious rats with malignant two-kidney Goldblatt hypertension.
    Filep J; Frölich JC; Fejes-Tóth G
    Clin Exp Hypertens A; 1985; 7(7):1007-14. PubMed ID: 3840065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of AVP in malignant DOC-salt hypertension: studies using vascular and antidiuretic antagonists.
    Filep J; Frölich JC; Földes-Filep E
    Am J Physiol; 1987 Nov; 253(5 Pt 2):F952-8. PubMed ID: 3688242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of vasopressin to the maintenance of blood pressure in deoxycorticosterone-salt induced malignant hypertension in spontaneously hypertensive rats.
    Hiwatari M; Abrahams JM; Saito T; Johnston CI
    Clin Sci (Lond); 1986 Feb; 70(2):191-8. PubMed ID: 3956109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does vasopressin sustain blood pressure in conscious spontaneously hypertensive rats?
    Filep J; Fejes-Tóth G
    Hypertension; 1986 Jun; 8(6):514-9. PubMed ID: 2872162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of vasopressin and other pressor systems to DOC-salt hypertension in rats.
    Mento PF; Wang HH; Sawyer WH
    Proc Soc Exp Biol Med; 1984 Jan; 175(1):58-63. PubMed ID: 6694969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.
    Möhring J; Möhring B; Petri M; Haack D
    Am J Physiol; 1977 Mar; 232(3):F260-9. PubMed ID: 842673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and heart rate effect of a vasopressin antagonist in conscious normotensive rats pretreated with exogenous vasopressin.
    Waeber B; Nussberger J; Brunner HR
    Eur J Pharmacol; 1983 Jul; 91(1):135-7. PubMed ID: 6688586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressor response to vasopressin and impaired baroreflex function in DOC-salt hypertension.
    Matsuguchi H; Schmid PG
    Am J Physiol; 1982 Jan; 242(1):H44-9. PubMed ID: 7058912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pressor response to vasopressin and norepinephrine in DOC-salt hypertensive and prehypertensive rats.
    Ouchi Y; Yazaki Y; Tsai RC; Ashida T
    Tohoku J Exp Med; 1988 Feb; 154(2):125-33. PubMed ID: 3381222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pressor responsiveness to vasopressin in the rat with DOC-salt hypertension.
    Crofton JT; Share L; Wang BC; Shade RE
    Hypertension; 1980; 2(4):424-31. PubMed ID: 7399626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of vasopressin-induced coronary artery constriction by the vasopressin antagonist d(CH2)5Tyr(Me)-AVP.
    Kopia GA; Valocik RE
    J Cardiovasc Pharmacol; 1985; 7(5):958-63. PubMed ID: 2413308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endothelin and vasopressin in DOCA-salt hypertension.
    Yu M; Gopalakrishnan V; McNeill JR
    Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central mechanisms in DOC-salt hypertensive rats.
    Matsuguchi H; Sharabi FM; O'Connor G; Mark AL; Schmid PG
    Clin Exp Hypertens A; 1982; 4(8):1303-21. PubMed ID: 7116668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of vasopressin as a pressor agent.
    Hofbauer KG; Studer W; Mah SC; Michel JB; Wood JM; Stalder R
    J Cardiovasc Pharmacol; 1984; 6 Suppl 2():S429-38. PubMed ID: 6206352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats.
    Szczepańska-Sadowska E; Paczwa P; Loń S; Ganten D
    J Hypertens; 1998 Oct; 16(10):1505-14. PubMed ID: 9814623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin and sympathetic nervous functions both contribute to development and maintenance of hypertension in DOCA-salt rats.
    Takata Y; Yamashita Y; Takishita S; Fujishima M
    Clin Exp Hypertens A; 1988; 10(2):203-27. PubMed ID: 3370846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an intracerebroventricularly administered vasopressin V1 antagonist on blood pressure and heart rate in deoxycorticosterone-salt hypertensive rats.
    Toba K; Ouchi Y; Liang J; Akishita M; Orimo H
    J Auton Nerv Syst; 1994 Dec; 50(2):123-9. PubMed ID: 7884152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does vasopressin contribute to salt-induced hypertension in the Dahl strain?
    Matsuguchi H; Schmid PG; Van Orden D; Mark AL
    Hypertension; 1981; 3(2):174-81. PubMed ID: 7216372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.